Nanotherapeutics for Alzheimer’s Disease (AD): Tailored Delivery, Neuroprotection, and Disease Abatement

Introduction

Alzheimer’s Disease (AD) is one of the highly prevalent, most complex, and destructive neurodegenerative disorders. Complete cure of the disease is still illusive and treatment still involves symptomatic therapeutic interventions. The critical challenges, like penetration of the blood-brain barrier (BBB), targeted delivery of active molecules and scaffolds, and off-target toxicity, are still unmet. Nanotechnology in general and in nanomedicine in particular has offered a transformative path enabling the precision or targeted delivery via tailored nanoparticles. This has led to the effective crossing of drugs/active molecules through the BBB, targeted and sustained release of drugs/active molecules, theranostics, and early diagnosis, and modulation of oxidative stress and neuroinflammation at the nanoscale level. In the current thematic issue, cutting-edge nano-based therapeutic strategies for AD will be explored, and therapeutic innovations that can shift the focus from symptomatic treatment to disease-modifying interventions will be highlighted.

Keywords

Nanobiotechbology, Alzheimer's Disease, Nano-therapeutics, AI-Driven Drug Design for AD, Rising Frontiers in AD

Sub-topics

• Nanocarriers for the penetration of the BBB 
  • Polymeric/ Lipid-based Nanoparticles, dendrimers, and exosomes. 
  • Strategies like cell-penetrating peptide conjugation or receptor-mediated transcytosis

• Nanotherapeutics involving stimuli-responsive and multifunctional nanotherapeutics
  • pH, ROS, enzyme-responsive smart nanoparticles.
  • Multi-targeted delivery systems

• Nano-based theranostics for Alzheimer’s disease 
  • Coupled imaging and therapeutic agents.  
  • Diagnosis via nanoparticle-enriched biomarkers like amyloid beta. 

• RNA and Gene-based nanotherapeutics. 
  • SiRNA/miRNA or CRISPR-based delivery.

• Natural molecule-loaded Nanoparticles.
  • Resveratrol, Curcumin, Berberine, and EGCG-based nanoformulations for enhanced bioavailability.  

• Clinical Translation and Regulatory Challenges 
  • Safety, Toxicity evaluation, and Biodistribution. 

• Rising Frontiers 
  • Nano-vaccines and immune-therapeutics 
  • Brain-responsive biodegradable nanomaterials. 
  • Computer or AI-guided nanodrug design for AD.